Follicular Lymphoma - Pipeline Review, H1 2016

  • ID: 3759034
  • Drug Pipelines
  • 542 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Bio-Path Holdings, Inc.
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • Kite Pharma, Inc.
  • MorphoSys AG
  • MORE
Follicular Lymphoma - Pipeline Review, H1 2016

Summary

‘Follicular Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Follicular Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Follicular Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma
- The report reviews pipeline therapeutics for Follicular Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Follicular Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Follicular Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Follicular Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Bio-Path Holdings, Inc.
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • Kite Pharma, Inc.
  • MorphoSys AG
  • MORE
Introduction

Follicular Lymphoma Overview

Therapeutics Development

Follicular Lymphoma - Therapeutics under Development by Companies

Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes

Follicular Lymphoma - Pipeline Products Glance

Follicular Lymphoma - Products under Development by Companies

Follicular Lymphoma - Products under Investigation by Universities/Institutes

Follicular Lymphoma - Companies Involved in Therapeutics Development

Follicular Lymphoma - Therapeutics Assessment

Drug Profiles

Follicular Lymphoma - Recent Pipeline Updates

Follicular Lymphoma - Dormant Projects

Follicular Lymphoma - Discontinued Products

Follicular Lymphoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Follicular Lymphoma, H1 2016

Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Investigation by Universities/Institutes, H1 2016

Follicular Lymphoma - Pipeline by AbbVie Inc., H1 2016

Follicular Lymphoma - Pipeline by Affimed GmbH , H1 2016

Follicular Lymphoma - Pipeline by Bayer AG, H1 2016

Follicular Lymphoma - Pipeline by BeiGene, Ltd., H1 2016

Follicular Lymphoma - Pipeline by Bio-Path Holdings, Inc., H1 2016

Follicular Lymphoma - Pipeline by Biocon Limited, H1 2016

Follicular Lymphoma - Pipeline by Biogenomics Limited, H1 2016

Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016

Follicular Lymphoma - Pipeline by Celgene Corporation, H1 2016

Follicular Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016

Follicular Lymphoma - Pipeline by Celltrion, Inc., H1 2016

Follicular Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016

Follicular Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016

Follicular Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016

Follicular Lymphoma - Pipeline by Curis, Inc., H1 2016

Follicular Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2016

Follicular Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016

Follicular Lymphoma - Pipeline by EpiZyme, Inc., H1 2016

Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Follicular Lymphoma - Pipeline by Genentech, Inc., H1 2016

Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016

Follicular Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016

Follicular Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016

Follicular Lymphoma - Pipeline by Immune Design Corp., H1 2016

Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016

Follicular Lymphoma - Pipeline by Immunomedics, Inc., H1 2016

Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016

Follicular Lymphoma - Pipeline by Johnson & Johnson, H1 2016

Follicular Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016

Follicular Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Follicular Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016

Follicular Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016

Follicular Lymphoma - Pipeline by MedImmune, LLC, H1 2016

Follicular Lymphoma - Pipeline by Medivation, Inc., H1 2016

Follicular Lymphoma - Pipeline by MEI Pharma, Inc., H1 2016

Follicular Lymphoma - Pipeline by Merck & Co., Inc., H1 2016

Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016

Follicular Lymphoma - Pipeline by MorphoSys AG, H1 2016

Follicular Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016

Follicular Lymphoma - Pipeline by Novartis AG, H1 2016

Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Follicular Lymphoma - Pipeline by Pfizer Inc., H1 2016

Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016

Follicular Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016

Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016

Follicular Lymphoma - Pipeline by Sandoz International GmbH, H1 2016

Follicular Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016

Follicular Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Follicular Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016

Follicular Lymphoma - Dormant Projects, H1 2016

Follicular Lymphoma - Dormant Projects (Contd..1), H1 2016

Follicular Lymphoma - Dormant Projects (Contd..2), H1 2016

Follicular Lymphoma - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Follicular Lymphoma, H1 2016

Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc.
Affimed GmbH
Bayer AG
BeiGene, Ltd.
Bio-Path Holdings, Inc.
Biocon Limited
Biogenomics Limited
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai Co., Ltd.
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Immune Design Corp.
ImmunoGen, Inc.
Immunomedics, Inc.
Infinity Pharmaceuticals, Inc.
Johnson & Johnson
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Les Laboratoires Servier SAS
MedImmune, LLC
Medivation, Inc.
MEI Pharma, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
MorphoSys AG
Nordic Nanovector ASA
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmacyclics, Inc.
Portola Pharmaceuticals, Inc.
ProNAi Therapeutics, Inc.
Sandoz International GmbH
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll